BioPharma

29 March, 2023 | Wednesday | News

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. The Phase I CLINCH trial&n...

Lab

31 March, 2023 | Friday | News

Eppendorf adds digital documentation to connected electronic pipette system

The system's Liquid Manager feature offers predefined pipette settings and technique hints for a variety of liquids, ensuring consistent and accurate results in several applications. Users can also define their...

BioTech

31 March, 2023 | Friday | Company results

Genscript Biotech Reports 2022 Annual Results

Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximately US$490.1 million for the...

Contract Services

01 April, 2023 | Saturday | News

ABIONYX Pharma Unveils Ophthalmology Strategy and Positive Preclinical Results for Innovative Technologies.

Very promising preclinical results of the apoA-I biovector in an acute inflammation model Development of safe corticoids to limit traditional corticoid-related side effects when used in AMD or DME Project t...

Consumer Health

29 March, 2023 | Wednesday | News

Verbal Beginnings Partners with The Clinician for Autism Patient Reported Outcomes Program

The program will enable Verbal Beginnings' clients, families, and caregivers to remotely report on the health outcomes that matter most to them, including social communication, behavioral functioning, and quali...


White Paper

Bio Invest

31 March, 2023 | Friday | Company results

Genscript Biotech Reports 2022 Annual Results

Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close